Thanks, George. 8-K/A today, two weeks for DARA, not four....
Item 2.02. Results of Operations and Financial Condition
On February 28, 2008, Pharmacopeia, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period and year ended December 31, 2007 (the “Press Release”). A copy of the Press Release was furnished as Exhibit 99.1 to this report originally filed on February 28, 2008.
On February 28, 2008, after the issuance of the Press Release and the original filing of this report, management realized that there was a typographical error in the last sentence of the first bulleted paragraph of the Press Release. That sentence referred to previously reported top line results from the MAD trial, but instead of stating that it “showed all doses of PS433540 up to 1,000 mg daily for 2 weeks to be safe and well-tolerated”, it stated that it “showed all doses of PS433540 up to 1,000 mg daily for 4 weeks to be safe and well-tolerated.”
Attached hereto as Exhibit 99.1 is the first bulleted paragraph of the Press Release that reflects the correct language as described above.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. |
